INTRODUCTION/OBJECTIVES:Transvenous pacemakers are routinely used for pathologic bradyarrhythmias including third-degree atrioventricular block (3AVB), sick sinus syndrome (SSS), high-grade second-degree atrioventricular block (2AVB), and atrial standstill (AS). This study reports the multi-institutional complications and survival rates in a large cohort of dogs. ANIMALS, MATERIALS AND METHODS:A retrospective analysis of outcomes and complications in dogs that underwent transvenous pacemaker implantation between January 2000 and December 2016 at four academic institutions was conducted. RESULTS:In total, 595 dogs were identified (221 males and 374 females) with a median age of 10.1 years (range: 0.3-17.0 years). Presenting arrhythmias included 3AVB (54.5%), SSS (24.4%), high-grade 2AVB (16.1%), and AS (4.0%). Major complications occurred in 17.5% (104/595) of cases including lead dislodgement (n = 39), infection (n = 24), thrombus formation (n = 19), ventricular fibrillation (n = 8), cardiac arrest (n = 6), cardiac perforation (n = 5), and iatrogenic tricuspid stenosis (n = 3). Ventricular lead dislodgement in AS (20%) occurred more frequently than SSS (1.4%; P=0.002), and 80% of the ventricular leads that dislodged in dogs with AS were passive leads. Procedural mortality rate was 0.8% (5/595). Median survival time was 2.8 years (2AVB, 2.9 years; 3AVB, 2.9 years; AS, 3.3 years; SSS, 2.5 years). Cardiac mortality occurred in 60.0% of AS cases compared to 2AVB (25.0%), 3AVB (21.9%), and SSS (16.9%). STUDY LIMITATIONS:Limitations of this study included the retrospective nature of the project with some loss to follow-up. CONCLUSIONS:Pacemakers have a low procedural mortality rate, and overall, complications were minimal. Type of lead and underlying disease process may impact the risk of lead dislodgement. Dogs with AS are more likely to die from cardiac-related disease.

Introduction Time-and dose-dependent adverse effects of amiodarone have not been described in cats. The primary aim of this retrospective multicenter cohort study was to report the type and frequency of clinical adverse effects and biochemical changes in cats receiving amiodarone chronically. The secondary aim was to report survival outcomes in this population of cats.Methods Medical records were reviewed for signalment, arrhythmia diagnosis, presence of structural heart disease, systemic comorbidities and congestive heart failure at presentation, amiodarone dose, serial bloodwork results, adverse events, and survival outcome.Results The study population included 27 client-owned cats (2016-2022). All cats had structural cardiac disease, and many were in congestive heart failure (17/27; 63%) at presentation. Amiodarone was most commonly prescribed for ventricular tachycardia (19/27, 70%), and it was administered once daily with a median [range] dose of 8.8 [4.515.2] mg/kg/day. There was a decrease in serum concentration of alanine transaminase between pretreatment values and values measured during the early amiodarone treatment window, 1-90 days (n = 16; p = 0.034). No statistical difference in serum concentration of alanine transaminase (n = 10; p = 0.799) was noted after 90 days of treatment compared to pretreatment. There was no change in hematocrit, neutrophil count, and serum concentration of alkaline phosphatase and total thyroxine during treatment in assessed cats. Ten cats (37%) had at least one episode of hyporexia or vomiting while receiving amiodarone. The median survival time for all-cause mortality was 441 days (95% confidence interval, 126-929 days); cats in which the primary therapeutic target was both supraventricular and concomitant ventricular tachyarrhythmias had at least a two-fold risk of dying compared to cats with supraventricular tachyarrhythmias alone (hazard ratio 12.9, 95% CI 1.86-89.8; p = 0.010).Discussion Amiodarone was primarily used to treat ventricular arrhythmias. Transient gastrointestinal signs were reported in approximately one-third of the cats studied, but no clinically significant laboratory abnormalities were found in cats receiving amiodarone.

A 6-year-old spayed female Goldendoodle was presented as a referral for bradycardia and collapse. An electrocardiogram revealed a high-grade second-degree atrioventricular block (HG2AVB) with atrial flutter. The patient was hospitalized overnight with the intention of pacemaker placement the following morning. Following bolus administration of atropine and lidocaine to rule out high vagal tone, the patient was placed on an atropine continuous rate infusion (CRI) to increase heart rate overnight. This resulted in an acute onset of suspected delirium, which lasted several hours following cessation of the CRI. The patient proceeded with pacemaker placement the following day. No further neurological events were noted at 1 year after pacemaker placement. Atropine-associated delirium should be considered in any patient where high cumulative doses of atropine are being considered.

A dog with immune-mediated thrombocytopenia and a new heart murmur had an echocardiogram in 2016 and was found to have a suspected aorto-left atrial fistula. The echocardiogram findings remained relatively static from 2016 to 2022. This report highlights the use of cardiac-gated computed tomography angiography to allow further understanding of a complex anomaly in a patient with a ruptured sinus of Valsalva aneurysm causing a fistulous connection with the left atrium. (c) 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

•PAs can protrude from the lung with severe obstruction and dilation.•Dogs can develop PT secondary to protein-losing nephropathy.•Evidence of classic histopathologic changes associated with chronic PH was present.•Dogs can live with chronic severe PA obstruction and severe PH secondary to PT.

Positive clinical outcomes of a group of surviving puppies from a litter affected by parvoviral myocarditis are detailed in this case report. Past reports focus on the negative outcomes of littermates of puppies who have died of parvoviral myocarditis. In this case, two puppies in a shelter setting, from a litter exposed to parvovirus, died suddenly with parvoviral myocarditis diagnosed at necropsy. The other seven puppies were screened for cardiac health with echocardiogram, electrocardiogram, and cardiac troponin I prior to adoption. All seven puppies had normal echocardiograms, electrocardiograms, and normal initial and recheck cardiac troponin I results. At recheck 2 years after the initial round of testing, two of the puppies were screened and continue to have normal cardiac diagnostics. All seven dogs are alive and thriving at 5 years old in homes with adopters who were given a complete medical history on the dogs prior to adoption. In summary, the outcomes for puppies in litters affected by parvoviral myocarditis are variable but they do not have to be grave. The use of cardiac diagnostics including echocardiogram, electrocardiogram and cardiac troponin I may serve as a prognostic basis for assessing the potential outcomes for the surviving puppies in affected litters.

•Migrating grass awns should be a differential diagnosis for pericardial effusion.•Pericardial FBs can result in life-threatening pericarditis and epicarditis.•TTE can be used to diagnose a pericardial FB.•On TTE, absent RAu with pericardial effusion should cause suspicion of epicarditis.•Subtotal pericardiectomy can be curative for pericardial FBs.

•Diastolic retrograde flow may be seen in the Ao in a dog with severe AR.•Holodiastolic retrograde flow is described in people, typically in the descending Ao.•Holodiastolic retrograde flow within the Ao has not been reported in dogs.•Retrograde diastolic flow in the ascending Ao perfuses the CAs; undetectable on TTE.

INTRODUCTION:The objective of this retrospective study was to describe the indications, complications, and long-term outcomes in a group of cats that received an epicardial pacing (EP) system. ANIMALS:Twenty client-owned cats. MATERIALS AND METHODS:Medical records were reviewed for signalment, presenting complaint, primary electrocardiogram (ECG) diagnosis, presence of structural heart disease, presence of congestive heart failure (CHF), presence of major or minor complications, and survival time. RESULTS:The majority of cats were presented for syncope (n = 11), and the most common ECG diagnosis was advanced second-degree atrioventricular block (n = 9). Fifteen cats (15/20, 75%) had one or more major or minor complications. One cat died in the perioperative period as a result of a major complication. None of the variables evaluated were associated with a statistically significant increase in the occurrence of major or minor complications. The most common major complication was loss of ventricular capture (seven instances in six cats), which was successfully treated in all cases by increasing pacemaker output or replacing both the lead and the pulse generator. The most common minor complications were arrhythmias (n = 7) and sensing issues (n = 8). The overall median survival time (MST) was 948 days. No statistical difference in survival time was identified between cats that experienced a major complication and those that did not. CONCLUSIONS:Although complications were common in this feline population after EP, major and minor complications were successfully treated.

The updated VCOG-CTCAE v2 guidelines contain several important updates and additions since the last update (v1.1) was released in 2011 and published within Veterinary and Comparative Oncology in 2016. As the Veterinary Cooperative Oncology Group (VCOG) is no longer an active entity, the original authors and contributors to the VCOG-CTCAE v1.0 and v1.1 were consulted for input, and additional co-authors sought for expansion and refinement of the adverse event (AE) categories. VCOG-CTCAE v2 includes expanded neurology, cardiac and immunologic AE sections, and the addition of procedural-specific AEs. It is our intent that, through inclusion of additional authors from ACVIM subspecialties and the American College of Veterinary Surgery, that we can more comprehensively capture AEs that are observed during clinical studies conducted across a variety of disease states, clinical scenarios, and body systems. It is also our intent that these updated veterinary CTCAE guidelines will offer improved application and ease of use within veterinary practice in general, as well as within clinical trials that assess new therapeutic strategies for animals with a variety of diseases. Throughout the revision process, we strived to ensure the grading structure for each AE category was reflective of the decision-making process applied to determination of dose-limiting events. As phase I trial decisions are based on these criteria and ultimately determine the maximally tolerated dose, there is impact on standard dosing recommendations for any new drug registration or application. This document should be updated regularly to reflect ongoing application to clinical studies carried out in veterinary patients.

Associations of diet with dilated cardiomyopathy are under investigation. That cardiac assessment would show abnormalities in healthy dogs eating grain-free (GF) diets or diets with Food and Drug Administration (FDA)-listed ingredients of concern (peas, lentils, or potatoes) as top 10 ingredients (FDA-PLP), but not in dogs eating grain-inclusive (GI) diets or diets without FDA-listed ingredients of concern (PLP) in the top 10 ingredients (NoFDA-PLP). One hundred eighty-eight healthy Doberman Pinschers, Golden Retrievers, Miniature Schnauzers, and Whippets. This study was an observational cross-sectional study. Echocardiograms, cardiac biomarkers, and blood and plasma taurine concentrations were compared between dogs eating GF (n = 26) and GI (n = 162) diets, and between FDA-PLP (n = 39) and NoFDA-PLP (n = 149) diets, controlling for age and breed. Demographic characteristics, murmurs, genetic status, and ventricular premature complexes (VPCs) during examination were compared between dogs eating different diet types. No differences in echocardiographic variables, N-terminal pro-B-type natriuretic peptide or whole blood taurine were noted between dogs eating different diet types. Dogs eating GF diets had higher median high-sensitivity cardiac troponin I (hs-cTnI) (GF 0.076 ng/mL [Interquartile range (IQR), 0.028-0.156] vs. GI 0.048 [IQR, 0.0026-0.080]; P < .001) and higher median plasma taurine (GF 125 nmol/mL [IQR, 101-148] vs GI 104 [IQR, 86-123]; P = .02) than dogs eating GI diets. Dogs eating FDA-PLP diets had higher median hs-cTnI (0.059 ng/mL [IQR, 0.028-0.122]) than dogs eating NoFDA-PLP diets (0.048 [IQR, 0.025-0.085]; P = .006). A greater proportion of dogs eating FDA-PLP diets (10%) had VPCs than dogs eating NoFDA-PLP diets (2%; P = .04 ) . Higher hs-cTnI in healthy dogs eating GF and FDA-PLP diets might indicate low-level cardiomyocyte injury.

AbstractBackgroundAssociations of diet with dilated cardiomyopathy are under investigation.ObjectivesThat cardiac assessment would show abnormalities in healthy dogs eating grain‐free (GF) diets or diets with Food and Drug Administration (FDA)‐listed ingredients of concern (peas, lentils, or potatoes) as top 10 ingredients (FDA‐PLP), but not in dogs eating grain‐inclusive (GI) diets or diets without FDA‐listed ingredients of concern (PLP) in the top 10 ingredients (NoFDA‐PLP).AnimalsOne hundred eighty‐eight healthy Doberman Pinschers, Golden Retrievers, Miniature Schnauzers, and Whippets.MethodsThis study was an observational cross‐sectional study. Echocardiograms, cardiac biomarkers, and blood and plasma taurine concentrations were compared between dogs eating GF (n = 26) and GI (n = 162) diets, and between FDA‐PLP (n = 39) and NoFDA‐PLP (n = 149) diets, controlling for age and breed. Demographic characteristics, murmurs, genetic status, and ventricular premature complexes (VPCs) during examination were compared between dogs eating different diet types.ResultsNo differences in echocardiographic variables, N‐terminal pro‐B‐type natriuretic peptide or whole blood taurine were noted between dogs eating different diet types. Dogs eating GF diets had higher median high‐sensitivity cardiac troponin I (hs‐cTnI) (GF 0.076 ng/mL [Interquartile range (IQR), 0.028‐0.156] vs. GI 0.048 [IQR, 0.0026‐0.080]; P < .001) and higher median plasma taurine (GF 125 nmol/mL [IQR, 101‐148] vs GI 104 [IQR, 86‐123]; P = .02) than dogs eating GI diets. Dogs eating FDA‐PLP diets had higher median hs‐cTnI (0.059 ng/mL [IQR, 0.028‐0.122]) than dogs eating NoFDA‐PLP diets (0.048 [IQR, 0.025‐0.085]; P = .006). A greater proportion of dogs eating FDA‐PLP diets (10%) had VPCs than dogs eating NoFDA‐PLP diets (2%; P = .04).Conclusions and Clinical ImportanceHigher hs‐cTnI in healthy dogs eating GF and FDA‐PLP diets might indicate low‐level cardiomyocyte injury.

Abstract Pulmonary hypertension (PH), defined by increased pressure within the pulmonary vasculature, is a hemodynamic and pathophysiologic state present in a wide variety of cardiovascular, respiratory, and systemic diseases. The purpose of this consensus statement is to provide a multidisciplinary approach to guidelines for the diagnosis, classification, treatment, and monitoring of PH in dogs. Comprehensive evaluation including consideration of signalment, clinical signs, echocardiographic parameters, and results of other diagnostic tests supports the diagnosis of PH and allows identification of associated underlying conditions. Dogs with PH can be classified into the following 6 groups: group 1, pulmonary arterial hypertension; group 2, left heart disease; group 3, respiratory disease/hypoxia; group 4, pulmonary emboli/pulmonary thrombi/pulmonary thromboemboli; group 5, parasitic disease (Dirofilaria and Angiostrongylus); and group 6, disorders that are multifactorial or with unclear mechanisms. The approach to treatment of PH focuses on strategies to decrease the risk of progression, complications, or both, recommendations to target underlying diseases or factors contributing to PH, and PH‐specific treatments. Dogs with PH should be monitored for improvement, static condition, or progression, and any identified underlying disorder should be addressed and monitored simultaneously.

This chapter deals with pulmonary hypertension (PH) in dogs, discussing the etiology/pathophysiology, epidemiology, signalment, history and clinical signs, physical examination, diagnosis, therapy, and prognosis. The three main components involved in PH development are the endothelin pathway, the prostacyclin pathway, and the nitric oxide pathway. The typical signalment of the patient with PH is a middle-aged to older small-breed dog, which reflects the population of dogs that are predisposed to myxomatous mitral valve disease and chronic pulmonary disease. The chapter outlines four diagnostic techniques for PH: right heart catheterization, thoracic radiography, electrocardiogram, and echocardiogram. The goals of treatment for patients with PH are to treat the underlying disease, improve clinical signs, lower pulmonary artery pressure, improve right ventricular function, prolong survival, and improve quality of life.

Objectives: The objective of this study was to report the signalment, presentation, clinical and imaging findings, interventions, and outcomes in a group of dogs with cor triatriatum dexter (CTD). Animals: Seventeen client-owned dogs. Methods: Medical records were reviewed retrospectively for signalment, history, physical examination findings, imaging and diagnostic findings, presence of concur rent congenital cardiac defects, description of interventional procedures, therapy information, and outcomes. Results: Age at presentation ranged from two to 110 months, with 10 of 17 dogs (59%) aged <12 months. There was an equal distribution between the sexes. Peritoneal effusion was the most common presenting complaint, in 10 of 17 dogs (59%). The CTD was an isolated finding in 3 of 17 dogs (18%); the remaining 14 of 17 (82%) dogs had concurrent cardiac disease, with congenital anomalies present in 12 of 17 (70%). All except one of these 12 dogs had at least one additional condition affecting the right heart. Tricuspid valve dysplasia was the most common congenital comorbidity, present in 9 of 17 dogs (53%). Seven dogs (41%) underwent interventional treatment of their CTD. In 7 of 17 (41%) cases, the CTD was considered to be incidental and the dogs were asymptomatic; therefore, no interventions were performed. The remaining three cases were euthanized or lost to follow-up. Conclusions: Cor triatriatum dexter in dogs is commonly seen in association with other right-sided congenital cardiac anomalies and may be an incidental finding. Dogs with CTD obstructing right atrial inflow can have a good outcome after intervention. Dogs with no clinical signs associated with the CTD may remain asymptomatic into adulthood. (C) 2019 Elsevier B.V. All rights reserved.

Four dogs, referred for management of heartworm (HW) disease, were found to have HWs entangled in their tricuspid valve apparatus. None of the dogs were actively hemolyzing or showed signs of acute cardiovascular collapse that would have necessitated emergency transvenous HW extraction, and surgery was not performed at time of presentation. The dogs received pimobendan and sildenafil within 24 h of identifying HW in the tricuspid valve apparatus, and the HW moved to the pulmonary arteries within 2 days in most cases (median 2 days, range 1-14 days). All dogs survived to discharge from the original hospital admission and were subsequently treated with adulticide (melarsomine) without complication. AR dogs were HW antigen negative 6 months after their last melarsomine injection. Four dogs appeared to respond positively to medical management aimed at decreasing pulmonary arterial pressure and improving the right ventricular function, but movement of HW out of the heart for other reasons cannot be excluded. This therapeutic option is not advised when dogs with NW disease are presented for acute collapse, ongoing hemolysis, and hypotension as surgical extraction is still considered the best option in these cases. It remains unknown if medical management is a safe option for all dogs with intracardiac HW without clinical signs of caval syndrome. Controlled prospective studies are required to determine the efficacy and safety of this treatment regimen in comparison with surgical extraction. (C) 2019 Elsevier B.V. All rights reserved.

Chronic thromboembolic pulmonary hypertension (CTEPH) is a debilitating disease that progresses to right ventricular (RV) failure and death if left untreated. Little is known regarding the progression of RV failure in this disease, greatly limiting effective prognoses, and therapeutic interventions. Large animal models enable the use of clinical techniques and technologies to assess progression and diagnose failure, but the existing large animal models of CTEPH have not been shown to replicate the functional consequences of the RV, i.e., RV failure. Here, we created a canine embolization model of CTEPH utilizing only microsphere injections, and we used a combination of right heart catheterization (RHC), echocardiography (echo), and magnetic resonance imaging (MRI) to quantify RV function. Over the course of several months, CTEPH led to a 6-fold increase in pulmonary vascular resistance (PVR) in four adult, male beagles. As evidenced by decreased cardiac index (0.12 ± 0.01 v. 0.07 ± 0.01 [L/(min*kg)]; p < 0.05), ejection fraction (0.48 ± 0.02 v. 0.31 ± 0.02; p < 0.05), and ventricular-vascular coupling ratio (0.95 ± 0.09 v. 0.45 ± 0.05; p < 0.05), as well as decreased tricuspid annular plane systolic excursion (TAPSE) (1.37 ± 0.06 v. 0.86 ± 0.05 [cm]; p < 0.05) and increased end-diastolic volume index (2.73 ± 0.06 v. 2.98 ± 0.02 [mL/kg]; p < 0.05), the model caused RV failure. The ability of this large animal CTEPH model to replicate the hemodynamic consequences of the human disease suggests that it could be utilized for future studies to gain insight into the pathophysiology of CTEPH development, following further optimization.

Abscess formation in the pericardial space has been described as a rare complication of trauma, congenital defects, penetrating foreign body, or extension of local myocardial infection in the dog. Presented here is a case of a juvenile dog with septic pericardial effusion secondary to an isolated intrapericardial abscess. Surgical pericardiectomy was successful in removing the abscess and nidus for septic effusion in this patient, and histopathology of the abscess tissue was suggestive of foreign plant material migration as the nidus for abscess formation. Recheck echocardiogram at the six-month postoperative period showed no recurrence of pericardial effusion or abscessation. Although abscess formation and septic pericarditis secondary to foreign body migration is an uncommon cause for large volume pericardial effusion, this should be considered as a differential particularly in a young and previously healthy dog.

A 3-month-old, 9.9 kg, male pit bull cross was referred for evaluation of collapse. A left basilar systolic heart murmur graded V/VI and a grade IV/VI right basilar systolic heart murmur were ausculted. Echocardiography showed severe pulmonic stenosis characterized by annular hypoplasia, leaflet thickening, and leaflet fusion. After 1 month of atenolol therapy, a pulmonic valve balloon valvuloplasty procedure was performed, and the intra-operative right ventricular pressure was reduced by 43%. Echocardiography, performed the following day, showed apparent rupture of a pulmonary valve leaflet and a membranous structure within the pulmonary artery consistent with a dissecting membrane. Short-term follow-up has shown no apparent progression of the pulmonary artery dissection and the patient remains free of clinical signs.

Objectives: To assess the prevalence of functional ejection murmurs and murmurs of mitral regurgitation (MR) due to myxomatous mitral valve disease in healthy whippets; to assess the diagnostic value of auscultation to detect MR; and investigate the relationship between age and presence of echocardiographically documented MR (MRecho). Animals: A total of 200 healthy client-owned Whippets, recruited at national shows between 2005 and 2009 were involved in this study.Methods: Cross-sectional study. Dogs were examined by auscultation by one examiner and Doppler echocardiography by another, and results were compared. Prevalence of types of murmurs and MRecho were calculated and correlated to age. Accuracy of auscultation to predict MRecho was calculated.Results: Left-sided systolic heart murmurs were detected in 185/200 (93%) of dogs. Left apical systolic murmurs (Lapex) were detected in 57/200 (29%) and left basilar systolic murmurs (Lbase) in 128/200 of the dogs (64%). MRecho was present in 76/200 (38%) dogs. Prevalence MRecho was correlated with age (r = 0.96, p=0.0028). Mitral regurgitation detected by echocardiography was present in 12/78 (15%) of the dogs < 2 years of age and in 59% of the dogs at 7-8 years old. Detection of Lapex predicted MRecho with sensitivity 65%, specificity 94%, positive predictive value 86%, and negative predictive value 81%; and accuracy improved when only dogs with more intense Lapex (grade > 3/6) were considered.Conclusions: Systolic murmurs are common in North American Whippets and this breed exhibits a high prevalence of MRecho, which may be documented at a relatively early age. Whippets with non-clinical MRecho may not be identifiable by auscultation alone; echocardiographic examination may be required to exclude a diagnosis of MR. Louder heart murmurs allow more accurate localization in this population. (C) 2017 Elsevier B.V. All rights reserved.